Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-β 1a, and high doses of immunoglobulins

Multiple Sclerosis Journal - Tập 13 Số 3 - Trang 313-331 - 2007
Paola Sarchielli1, Mauro Zaffaroni2, A Floridi1, Laura A. Greco1, Antonio Candeliere-Merlicco3, Alessia Mattioni3, Serena Tenaglia3, Massimiliano Di Filippo3, Paolo Calabresi3
1Neurologic Clinic, Department of Medical and Surgical Specialties and Public Health, University of Perugia, Perugia 06158, Italy
2Center for the Study of Multiple Sclerosis, Ospedale S Antonio Abate, Via Pastori 4, I-21013 Gallarate (VA), Italy
3Neurologic Clinic, Department of Medical and Surgical Specialties and Public Health, University of Perugia, Perugia 06158, Italy, I.R.C.C.S., Fondazione Santa Lucia, Rome, Italy

Tóm tắt

Sixty, relapsing remitting (RR) multiple sclerosis (MS) patients, who underwent treatment with glatiramer acetate (GA), interferon (IFN)-β 1a, and immunoglobulins (Igs) (20 per treatment group), were assessed for levels of brain-derived neurotrophic factor (BDNF) in the supernatants of unstimulated and stimulated peripheral blood mononuclear cells (PBMCs) in the first year of treatment. Phytohemagglutinin (PHA), anti-OKT3 antibody, myelin basic protein (MPB) and GA were used as stimuli. Cytokine responses by ELISPOT and lymphoproliferative responses were also assessed. The GA-treated MS patient group showed a progressive increase in BDNF levels, from baseline to month three; thereafter, the levels remained stable and significantly greater compared with baseline and controls (ANOVA=P<0.001). IFN-β 1a had no effect on BDNF production, whereas Igs induced a slight decrease (ANOVA=P<0.04). ELISPOT analysis revealed a significant decrease of IFN-γ, an increase of interleukin (IL)-4 and IL-5 in GA-treated MS patients, and an increase of IL-10 in patients treated with IFN-β 1a and GA. No significant correlation was found between BDNF secretion in the supernatants of PBMCs and cytokine response, lesional load, and measures of atrophy. Increased BDNF production related to GA treatment can have implications for understanding the mechanism of action of this immunomodulatory agent, in light of evidence suggesting its effects in promoting neuroprotective immunity in MS patients; however, a clinically measurable effect, especially in terms of an impact on actual disease progression, remains to be established. Multiple Sclerosis 2007; 13: 313-331. http://msj.sagepub.com

Từ khóa


Tài liệu tham khảo

10.1016/S0039-6257(01)00208-9

10.1038/4734

10.1073/pnas.97.13.7446

10.1523/JNEUROSCI.20-14-05283.2000

Ikeda K., 1995, Ann Neurol, 37, 50511

10.1097/00005072-199801000-00001

10.1016/S0165-5728(00)00233-2

10.1016/S0169-328X(01)00314-X

10.1002/ana.10446

10.1007/s00415-004-0649-z

10.1016/S0140-6736(99)05140-5

10.1002/ana.410390117

Binder DK, 2004, Growth Factors, 22, 123, 10.1080/08977190410001723308

Marini AM, 2004, Restor Neurol Neurosci, 22, 121

Askanas V., 1995, Adv Neurol, 68, 241

10.1016/j.ejphar.2003.08.096

10.1016/S0301-0082(00)00014-9

10.1385/MN:29:1:15

10.1517/14728222.8.5.391

10.1002/j.1460-2075.1990.tb07423.x

10.1146/annurev.ne.19.030196.001445

Besser M., 1999, J Immunol, 162, 6303, 10.4049/jimmunol.162.11.6303

10.1165/ajrcmb.21.4.3670

10.1084/jem.189.5.865

10.1016/0167-5699(92)90024-2

10.1093/brain/awf015

10.1016/S0165-5728(02)00319-3

10.1046/j.1365-3083.2003.01260.x

10.1111/j.1365-3083.2005.01649.x

10.1191/1352458503ms869oa

10.1016/j.clim.2005.09.005

10.1093/brain/awf252

10.1007/978-1-4419-8969-7_7

10.1016/j.jns.2005.03.010

10.1073/pnas.2336171100

10.1523/JNEUROSCI.1859-05.2005

10.1002/ana.1032

10.1212/WNL.33.11.1444

Lublin FD, 1996, Neurology, 46, 907, 10.1212/WNL.46.4.907

10.1017/S0317167100000391

10.1007/s004150070054

10.1016/S0022-510X(03)00177-1

10.1111/j.1468-1331.2005.01084.x

10.1073/pnas.97.13.7452

10.1093/brain/124.4.705

10.1196/annals.1309.055

10.1073/pnas.0404887101

10.1016/j.intimp.2004.09.007

10.1172/JCI8970

10.1212/WNL.55.11.1704

LaSalle JM , Hafler DA T cell anergy. FASEB J 1994; 8: 601-608.

10.1016/S1521-6616(03)00020-2

10.1046/j.1471-4159.1995.64041780.x

10.1016/S0028-3908(98)00141-5

10.1093/brain/124.9.1803

10.1177/135245850100700107

10.1016/j.jns.2005.03.013

Thông tin
Thông tin xuất bản

Multiple Sclerosis Journal

Tập 13 Số 3

313-331

Thông tin tác giả